Get the Stockscreener App
2.30
10.16%
-0.26
After Hours:
2.31
0.01
+0.43%
Aadi Bioscience Inc stock is traded at $2.30, with a volume of 217.78K.
It is down -10.16% in the last 24 hours and down -16.06% over the past month.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
See More
Previous Close:
$2.56
Open:
$2.55
24h Volume:
217.78K
Relative Volume:
0.69
Market Cap:
$60.51M
Revenue:
$23.26M
Net Income/Loss:
$-63.41M
P/E Ratio:
-0.9746
EPS:
-2.36
Net Cash Flow:
$-64.56M
1W Performance:
-15.44%
1M Performance:
-16.06%
6M Performance:
+32.18%
1Y Performance:
+19.79%
1-Day Range:
$2.25
$2.56
1-Week Range:
$2.25
$2.72
52-Week Range:
$1.21
$3.812
Aadi Bioscience Inc Stock (AADI) Company Profile
Name
Aadi Bioscience Inc
Sector
Industry
Phone
424-473-8055
Address
17383 SUNSET AVENUE, PACIFIC PALISADES
Compare AADI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AADI
Aadi Bioscience Inc
|
2.30 | 60.51M | 23.26M | -63.41M | -64.56M | -2.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Aadi Bioscience Inc Stock (AADI) Latest News
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Yahoo Finance
All You Need to Know About Aadi Bioscience (AADI) Rating Upgrade to Buy - MSN
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference -February 24, 2025 at 08:01 am EST - Marketscreener.com
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference - GuruFocus.com
Aadi Bioscience cut to hold at Jefferies following Fyarro failure in solid tumors - MSN
3 US Penny Stocks With Market Caps Over $30M To Watch - Yahoo Finance
Aadi Bioscience names new CSO to advance ADC pipeline - Investing.com India
Aadi Bioscience names new CSO to advance ADC pipeline By Investing.com - Investing.com South Africa
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - Quantisnow
Peapod Lane Capital LLC Makes New $1.40 Million Investment in Aadi Bioscience, Inc. (NASDAQ:AADI) - MarketBeat
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Growth in Short Interest - MarketBeat
Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - Defense World
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Declines By 13.7% - MarketBeat
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025 - Quantisnow
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Decrease in Short Interest - Defense World
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Growth in Short Interest - MarketBeat
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Increase in Short Interest - Defense World
ACUTA CAPITAL PARTNERS, LLC Expands Stake in Aadi Bioscience Inc - GuruFocus.com
Aadi Bioscience, Inc. (NASDAQ:AADI) Position Lowered by Jane Street Group LLC - Defense World
Aadi Bioscience, Inc. (NASDAQ:AADI) Shares Sold by Jane Street Group LLC - MarketBeat
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Rises By 136.0% - Defense World
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Grows By 136.0% - MarketBeat
Aadi Bioscience (NASDAQ:AADI) Shares Down 16.1% – What’s Next? - Defense World
Aadi Bioscience (NASDAQ:AADI) Trading Down 16.1%What's Next? - MarketBeat
Aadi Bioscience Enters Into Multiple Strategic Agreements, Including $100M Stock Purchase and License Agreement - Defense World
Aadi Bioscience, Inc. announced that it expects to receive $100.002392 million in funding from a group of investors - Marketscreener.com
Aadi Bioscience Sale of FYARRO® to Kaken Pharmaceutical and In-Licensing of Novel ADC Portfolio from WuXi Biologics - Leerink Partners
Aadi Bioscience Leads 3 Promising US Penny Stocks - Simply Wall St
Aadi Bioscience rockets 72% on key updates - MSN
Aadi Bioscience’s Strategic Agreements and Funding Moves - Yahoo Finance
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini
Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - Citeline
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Benzinga
Aadi Bioscience stock soars on licensing and sale deals - Investing.com India
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - Marketscreener.com
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing - Yahoo Finance
Kaken Pharmaceutical Co., Ltd. agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - Marketscreener.com
Clinical Trials News Live Feed - StockTitan
AADI Enlists NY Court To Enforce Cancer Drug Award - Law360
Aadi Bioscience Inc Stock (AADI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aadi Bioscience Inc Stock (AADI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lennon David James | CHIEF EXECUTIVE OFFICER |
Oct 03 '24 |
Sale |
1.94 |
9,689 |
18,797 |
22,869 |
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):